Abstract Advancing the clinical utility of whole-exome sequencing (WES) for patients with suspected genetic disorders is largely driven by bioinformatics approaches that streamline data processing and analysis. Herein, we describe our experience with implementing a semiautomated and phenotype-driven WES diagnostic workflow, incorporating both the DRAGEN pipeline and the Exomiser variant prioritization tool, at an academic children's hospital with an ethnically diverse pediatric patient population. We achieved a 41% molecular diagnostic rate for 66 duo-, quad-, or trio-WES cases, and 28% for 40 singleton-WES cases. Preliminary results were returned to ordering physicians within 1 wk for 12 of 38 (32%) probands with positive findings, which were instrumental in guiding the appropriate clinical management for a variety of patients, especially in critical care settings. The semiautomated and streamlined WES workflow also enabled us to identify novel variants in candidate disease genes in patients with developmental delay and autism and immune disorders and cancer, including ANK2, BPTF, BCL11A, FOXN1, PLAA, ATRX, DNAJC21, and RAD50. Together, we demonstrated the implementation of a streamlined WES workflow that was successfully applied for both clinical and research purposes.
INTRODUCTION
Whole-exome sequencing (WES) has been enormously successful for both novel disease gene discovery (Bamshad et al. 2011; Ku et al. 2012) and in the clinical diagnostic setting to determine the genetic causes of rare Mendelian (monogenic) disorders (Lee et al. 2014; Yang et al. 2014; Farwell et al. 2015) . Over the past few years, with the wide application of WES, a rich framework of experimental and analytical approaches has been established for elucidating the genes responsible for Mendelian disorders (Bamshad et al. 2011) . Technical and informatics advancements have led to reduced cost and turnaround time, as well as increased diagnostic yield and impact on patients' outcomes. The success rate has varied Ontology terms: abnormality of the cerebral vasculature; acute myeloid leukemia; aggressive behavior; ambiguous genitalia, male; aplasia of the thymus; astrocytoma; ataxia; autism; bilateral cryptorchidism; cleft palate; delayed social development; generalized hypotonia due to defect at the neuromuscular junction; generalized tonic seizures; microcephaly; osteosarcoma; retinoblastoma; severe T-cell immunodeficiency; severe global developmental delay; short stature; webbed neck significantly across laboratories primarily because of (1) technical differences in capturing and sequencing approaches, (2) the patient population being studied and possible ascertainment bias, (3) the availability of large reference databases, (4) the bioinformatics pipelines used, and, most importantly, (5) a highly variable practice of variant interpretation, which has been largely manual and has not consistently followed unified guidelines. The overall WES diagnostic rate in unselected, consecutive patients has been reported to be ∼25% (Lee et al. 2014; Yang et al. 2014; Farwell et al. 2015; Dragojlovic et al. 2018) . The efficiency of data analysis is limited by the need for multiple manual data interpretation steps, limited communication with ordering physicians, and, most importantly, limited adaptation of robust informatics tools to facilitate prioritization of variants.
Herein, we describe our clinical and research findings with implementing a semiautomated and phenotype-driven WES diagnostic workflow at a large academic children's hospital with an ethnically diverse pediatric patient population. The workflow was implemented, validated, and optimized using validation samples with known molecular diagnoses and then applied prospectively to clinical cases. We implemented the Edico DRAGEN Genome pipeline for rapid (∼4-min) variant calling, used standardized phenotypic description Human Phenotype Ontology (HPO) terms for primary gene selection, and incorporated Exomiser for automated variant prioritization. Using these approaches, results can be obtained in 72 h and can thus positively impact patient management in critical care settings. This workflow has a proven ability to identify novel variants and novel candidate disease genes automatically, especially for patients with developmental and immunologic disorders.
RESULTS

Clinical Presentation and Family History
The 106 clinical cases were referred from nine clinical divisions at the Children's Hospital Los Angeles including Medical Genetics (39), Neurology (26), Immunology (17), Neonatology and Pulmonology (12), Hematology & Oncology (5), Endocrinology (3), Dermatology (2), General Pediatrics (1), and Ophthalmology (1) (Fig. 1A) . These included 40 singletons (proband only), 60 trios (typically proband and both parents), 5 duos (proband and one parent), and 1 quad (proband, parents, and affected sibling). Of the 106 probands, there were 63 (59%) males and 43 (41%) females. Patients' age at the time of referral varied from newborn to 22 yr (median age 3 yr) (Supplemental Table 1 ). Patients presented with a range of phenotypes, as indicated by the 521 HPO terms mapped to patients' clinical phenotypes (Supplemental Table 1 ). The most common clinical indications included "global developmental delay" (29%), "seizures" (21%), "generalized hypotonia" (19%), "microcephaly" (10%), "cognitive impairment" (9%), "short stature" (9%), "cleft palate" (8%), "immunodeficiency" (8%), "autism" (8%), "failure to thrive" (8%), "abnormality of the cerebral white matter" (8%), "delayed speech and language development" (7%), and "cryptorchidism" (7%) (Fig. 1B) . The majority of patients had negative chromosomal microarray (CMA) results and many had single gene or gene panel testing that was uninformative. Three patients with positive CMA results were referred for WES because of concern for a second genetic disorder.
WES Molecular Diagnoses and Findings
A total of 40 molecular diagnoses were obtained in 38 of 106 patients, achieving an overall diagnostic rate of 36%. The diagnostic rate was 28% (11/40) for singleton-WES and 41% (27/ 66) for duo-, quad-, and trio-WES, respectively. The diagnostic yield for trio-WES is equal to or higher than 12 of the 13 exome studies of pediatric patient populations (Dragojlovic et al. 2018) . Of note, 42% (18/43) of patients between 1 and 5 years old had pathogenic or likely Whole-exome sequencing of pediatric patients
Molecular Case Studies pathogenic diagnostic findings, higher than the diagnostic rate of 27% (6/22) for patients younger than 12 mo, and 34% (14/41) for patients between 6 and 22 yr (Table 1;  Supplemental Table 1) . Further prospective studies with a significantly larger patient population are required to draw any conclusions from this interesting observation.
Thirty-eight patients received a total of 40 molecular diagnoses, of which 52.5% (21/40) were autosomal dominant (AD) diseases, 32.5% (13/40) were autosomal recessive (AR) diseases, and 15% (6/40) were X-linked diseases (Tables 1 and 2 ). De novo variants accounted for 67% (14/21) of AD conditions. Of the six patients with X-linked diseases, three had de novo variants (Tables 1, 2; Supplemental Table 1 ). Two patients (Patient 83 and 126) had dual molecular findings (Table 1) . Preliminary results were returned to the ordering physician in as few as 3 d and within 1 wk for 32% (12/38) of patients with positive findings, most of whom were in the neonatal intensive care unit. The timely delivery of the molecular diagnoses had an impact on the clinical management of these patients (see below). Follow-up family segregation analyses, particularly for singleton-WES cases, were helpful in further clarifying the variants' pathogenicity. For example, the pathogenic variant classification was further supported for Patients 104 and 126 in whom the variant was confirmed to be de novo in the proband using targeted Sanger sequencing on both parents. In contrast, we reclassified a hemizygous BCORL1 variant from variant of uncertain significance (VUS) to likely benign (Patient 69) because of its cosegregation in two other unaffected male siblings (WES study IDs: 148 and 177) (Supplemental Table 1) .
Interestingly, eight patients had a finding in genes associated with cancer predisposition (Table 3) . These included pathogenic variants in DNAJC21, RAD50, and ATRX identified in patients with cancer, a PMS2 nonsense variant detected in a patient with a family history of colon cancer, and MEN1, RET, BRCA2, and CHEK2 variants in patients without a clinical or Whole-exome sequencing of pediatric patients family history of cancer (Table 3) . Notably, we were the first to report ATRX as a potential cancer predisposition gene for osteosarcoma using our WES platform (Patient 72) (Ji et al. 2017) .
The association between a germline pathogenic ATRX variant and osteosarcoma was subsequently reported (Smolle et al. 2017; Masliah-Planchon et al. 2018 ).
Exomiser Results for WES Clinical Cases and Identification of Novel Candidate Variants
For the 43 reported pathogenic and likely pathogenic variants in 38 clinical cases, Exomiser ranked 72.1% (31/43) variants as the top candidate in 30 cases, 20.9% (9/43) in second to sixth place in seven cases, and 6.9% (3/43) at 27th place or not ranked in three cases (Table 1) . Together, 93% (40/43) of pathogenic or likely pathogenic variants were ranked in the top 6 by Exomiser. The Exomiser rank for sequencing variants identified in the clinical cases is shown in Table 1 .
Updated Molecular Diagnoses Using Recent Gene-Disease Associations
The highest rank by Exomiser initially for candidate variants in BPTF, DNAJC21, PLAA, and BCL11A were the second place, third place, 10th place, and the 52nd place for Patient 156, 132, 94, and 165, respectively (Table 4 ). There were no published disease associations with these genes when WES was initially performed, and therefore according to ACMG guidelines, they should not have been clinically reported. However, the nature of the variants indicated that these variants were potentially disease-causing. These four genes were later shown to have clear disease associations (Dias et al. 2016; Tummala et al. 2016; Hall et al. 2017; Stankiewicz et al. 2017 ). Stankiewicz et al. first described the gene disease association for BPTF, an AD neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (MIM: 617755) (Stankiewicz et al. 2017) , which largely overlaps with our patients' clinical presentation (Patient 156). This patient had a de novo truncating variant in BPTF. A homozygous canonical splice-site variant in PLAA was identified in a family (case 94) with two affected children suspected to have an AR disease. The PLAA gene was very recently shown to be associated with an AR neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies by Falik Zaccai et al. and Hall et al., subsequent to the original clinical study for this family (Falik Zaccai et al. 2017; Hall et al. 2017) . Similarly, since the time of the original analysis for Patient 132 new studies have been published that described an AR bone marrow failure syndrome (MIM: 617052) caused by germline biallelic pathogenic variants in DNAJC21 (Tummala et al. 2016; Dhanraj et al. 2017; Bluteau et al. 2018 ). The disorder 
De novo 14
Inherited from one of the parents 4
Inheritance unknown 2
Nonmaternal 1
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Compound heterozygous 2 X-linked recessive and dominant 6 (15%)
De novo 3
Hemizygous inherited from the heterozygous mother 3
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is characterized by onset of pancytopenia in early childhood. Patients may have additional variable nonspecific abnormalities, including poor growth, microcephaly, and skin anomalies (Tummala et al. 2016; Dhanraj et al. 2017) , which also fits the clinical presentation of our patient. The proband had a homozygous nonsense variant in DNAJC21 inherited in an AR manner from both parents who were heterozygous for this variant. Patient 165 had a novel BCL11A missense variant identified in a highly conserved region of the gene where missense variants are depleted in the general population (ExAC missense constraint z-score = 5.52).
Since the time of initial exome analysis, new publications have described the AD DiasLogan syndrome (MIM: 617101), caused by de novo heterozygous pathogenic variants in the BCL11A gene (Dias et al. 2016 ). The disorder is characterized by delayed psychomotor Whole-exome sequencing of pediatric patients Revised clinical reports were therefore issued that included the novel pathogenic or likely pathogenic variants for these patients. Our findings enrich the phenotypic characteristics of these newly established syndromes.
Identification of Candidate Variants in ANK2, RAD50, and FOXN1
Unlike the above described cases, exome analysis revealed a de novo heterozygous nonsense NM_001148.4:c.1417C > T (p.Arg473 * ) variant in the ANK2 gene for Patient 127 (Table 4) , who was referred for testing at age 5 yr with severe global developmental delay, seizures, aggressive behavior, and microcephaly. Pathogenic variants in ANK2 are known to be associated with AD ankyrin-B-related cardiac arrhythmia and long QT syndrome 4 (MIM: 600919), which did not explain the patient's primary clinical concerns. However, Exomiser ranked this variant in the first place likely because of its de novo and truncating nature. RNA-seq expression data from the Genotype-Tissue Expression Project suggests that ANK2 is expressed in brain tissue. Animal model experiments demonstrated that ank2 is required for synaptic stability in Drosophila (Koch et al. 2008) . Although the ANK2 gene currently has not yet been associated with any human neurodevelopmental phenotypes in the OMIM database, there is more evidence supporting a correlation between a de novo ANK2 variant and a human autism spectrum disorder and neurological phenotypes (Iossifov et al. 2012; Willsey et al. 2013; Farwell et al. 2015; Stessman et al. 2017) . We therefore consider this de novo truncating variant in ANK2 as a strong candidate to explain the patient's clinical phenotypes. More published data are needed to further support its association with a human neurological disorder.
Patient 135 had multiple primary tumors including unilateral retinoblastoma, astrocytoma, and a right shoulder granular cell tumor. RB1 gene sequencing and deletion/duplication testing was negative. WES revealed a heterozygous NM_005732.3:c.2165dupA (p.Glu723Glyfs * 5) variant in RAD50 (Table 4) . Germline heterozygous RAD50 loss-of-function mutations have been described in association with hereditary predisposition to cancers of the breast, ovary, fallopian tube, and peritoneum (Heikkinen et al. 2006; Walsh et al. 2011 ). Additionally, this variant is absent from the population data set gnomAD. However, based on currently available data, precise cancer risks associated with this gene are not well-described. It is also unclear whether germline pathogenic variants in RAD50 are associated with an increased risk for retinoblastoma and pilocytic astrocytoma seen in this patient. Additional studies on the tumor and parental studies may further inform the association between the pathogenic variant in RAD50 and the clinical presentation seen in this patient. We therefore considered this RAD50 frameshift variant to be another candidate variant for this patient's predisposition to cancer.
Our Exomiser analysis also highlights potential discovery of a new inheritance pattern for known disease genes. An example is the identification of a heterozygous NM_003593.2: c.1247delC (p.Pro416Glnfs * 134) frameshift variant in the FOXN1 gene in a 22-d-old male with severe T-cell immunodeficiency, aplasia of the thymus, with normal B and NK cells (Patient 194; Table 4 ). Pathogenic variants in FOXN1 are associated with AR T-cell immunodeficiency, congenital alopecia, and nail dystrophy (MIM: 601705). Although exome coverage for the FOXN1 exonic regions and splice-site junctions (5 bp into introns) was 100% at a minimum of 10× depth of coverage, a second possible variant, as expected for an AR disorder, was not identified by this analysis. The possibility this individual harbors a second variant, including a deletion or duplication of one or more exons or a variant in the intronic or regulatory regions that is undetectable by this test, cannot be excluded. However, a single
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heterozygous FOXN1 truncating variant without a second hit using whole-genome sequencing was observed in a different patient with similar phenotypes (data not published), which suggests a potential dominant inheritance for disease. Although no functional studies have been performed to test the effects of this particular variant on FOXN1 protein function or stability, this variant is expected to replace the carboxy-terminal portion of the FOXN1 with 134 aberrant amino acids. Additionally, the variant is not present in the population database gnomAD. Given that this is a frameshift variant in a gene in which frameshift variants are likely to cause disease, and the absence of this type of variant in the general population, we consider this variant likely pathogenic. Further functional and parental studies are warranted to further clarify its pathogenicity and its potential dominant inheritance.
WES Secondary Findings
Secondary findings deemed to be medically actionable were reported in nine of 101 patients who opted in to receive secondary findings (Supplemental Table 1 ). These included variants within the 59 genes recommended by the ACMG (Kalia et al. 2017) , as well as pathogenic or likely pathogenic variants in MEFV, MYOC, and CHEK2. As expected, for incidental findings, the Exomiser rank was much lower than for those relevant to patients' clinical phenotypes, with only 4/11 variants ranked between top 2 to 5.
Clinical Impact of Our Rapid WES Test
An accurate genetic diagnosis is essential for effective clinical management and may lead to modified treatment strategies, especially for pediatric patients compared to adults. We have implemented a WES workflow that allows for rapid diagnosis leading to improvements in patient management as exemplified by the following examples.
Patient 224 was an 11-mo-old male who presented with emesis, failure to thrive, hematochezia, and low serum concentration of IgG since age 5 mo. Endoscopy showed moderate to severe rectosigmoid colitis with ulcerations. The clinical picture was believed to reflect very early onset inflammatory bowel disease (VEO-IBD) prompting consideration of rare variants in NOD2 or IL10RA and IL10RB. Expedited WES was pursued and a maternally inherited XIAP NM_001167.3:c.562G > A (p.Gly188Arg) likely pathogenic hemizygous variant was identified. The results were returned to the ordering physician within 5 d. Follow-up targeted Sanger sequencing for the XIAP variant indicated that the mother was a heterozygous carrier for this variant who was not clinically affected. Pathogenic variants in XIAP are associated with X-linked recessive lymphoproliferative syndrome, type 2, which is characterized by primary immunodeficiency due to hemophagocytic lymphohistiocytosis and IBD. Allogeneic hematopoietic cell transplantation is the only curative treatment for this condition, and the patient's father is currently undergoing an evaluation to be a potential donor. This case highlights the ability to use WES to search beyond a narrow panel-based approach to obtain a diagnosis. In this case, and in similar ones reported previously (Kelsen et al. 2015; DeWeerdt 2016) , a correct, early diagnosis markedly changed management (allogeneic hematopoietic cell transplantation) and prevented the patient from having to endure ineffective treatments.
Patient 104 was a 5-wk-old male with neonatal onset diffuse hypotonia in conjunction with muscle weakness, microcephaly, and respiratory distress. The infant was unable to be weaned from oxygen, had inspiratory stridor, and required nasogastric tube feeding. Decisions regarding placement of a gastrostomy tube and utility of a muscle biopsy for diagnosis prompted a request for an expedited WES, which was conducted within 1 wk. Exome sequencing revealed a hemizygous NM_000252.2:c.1262G > T (p.Arg421Leu) pathogenic variant in MTM1, encoding myotubularin. Pathogenic variants in MTM1 are associated with X-linked recessive myotubular myopathy (XLMTM). XLMTM presents prenatally with decreased fetal movements and polyhydramnios and affected males have significant motor Whole-exome sequencing of pediatric patients
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Molecular Case Studies delays and most fail to achieve independent ambulation. After informed discussion with the family, the treatment team proceeded with G tube placement and plans for long-term ventilatory support were discussed. The health-care management plans for this patient will include long-term follow-up care with a pulmonologist and neurologist. Annual evaluations with an ophthalmologist are indicated to screen for ophthalmoplegia, ptosis, and myopia. For this patient, the family had consented to receive incidental findings. A heterozygous NM_000218.2:c.1085A > G (p.Lys362Arg) likely pathogenic variant in the KCNQ1 gene was detected as an incidental finding. Pathogenic variants in KCNQ1 are classically associated with long QT syndrome (MIM: 192500). This finding directly impacts follow-up and management of the patient, and further analysis revealed that the variant was inherited from the patient's father, who was then referred to a cardiologist for evaluation.
DISCUSSION
Incorporation of Exomiser into the Clinical Diagnostic Workflow Can Potentially Improve the Overall Diagnoses
Previous data have shown that phenotype-driven exome analysis and comparison of human to model organism phenotypes markedly improves the ability to identify candidate diseasecausing variants (Zemojtel et al. 2014; . However, this approach has yet to be proven in a clinical diagnostic setting. Our group customized and validated multiple bioinformatics tools, including Exomiser, for clinical diagnosis. The algorithms use model species (e.g., mouse, fish, rat), functional data, and protein-protein association data for inferring gene-variant-disease association through phenotype-driven associations . By effectively utilizing available phenotypic information, functional data, and genomic knowledge, phenotype-driven strategies can improve efficiency and diagnostic yield. We used an earlier version of Exomiser (version 7.2.1) at the time of WES analysis and the latest version at the end of this study (version 10.1.1). Novel variants in candidate genes, including BPTF, DNAJC21, PLAA, BCL11A, ANK2, FOXN1, and RAD50, were identified or supported using this approach, which combined with updated literature sources allowed us to resolve an additional three cases. Our diagnostic yield of 36% includes the four patients with pathogenic or likely pathogenic variants in ATRX, BPTF, BCL11A, and DNAJC21 as the phenotypes of these patients are consistent with the current literature (Dias et al. 2016; Tummala et al. 2016; Dhanraj et al. 2017; Smolle et al. 2017; Stankiewicz et al. 2017; Masliah-Planchon et al. 2018) . In a conservative fashion, at this time we have not included the patients with variants in ANK2, RAD50, FOXN1, and PLAA as the gene-disease association has not been fully established (ANK2, RAD50) ; the clinical phenotypes of our patient do not fit completely with what have been previously described (PLAA); or the observed potential inheritance pattern has not yet been proven (FOXN1). We anticipate that others may identify and report patients with similar clinical phenotypes that have pathogenic variants in at least some of these genes, which would further increase our diagnostic rate.
Cancer Predisposition
In this case series, a total of five patients had a clinical indication for cancer predisposition (Patient 58, 72, 132, 135, and 174) . Pathogenic or likely pathogenic variants were identified for four of the five patients (Table 3) ; three of which (ATRX, DNAJC21, and RAD50) were novel at the time of analysis. Additionally, four pathogenic or likely pathogenic variants were identified in known cancer predisposition genes as incidental findings, including variants in RET, MEN1, BRCA2, and CHEK2. The total number of patients with findings in a cancer gene is higher than expected, given the unselected nature of this patient population.
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Identifying these patients may lead to modified treatment strategies in cases of syndromerelated increased toxicity or resistant disease. Cancer surveillance is warranted for at-risk relatives. Ultimately, systematic monitoring of patients and family members who have germline cancer predisposition variants may allow for detection of cancers at their earliest and most curable stage, thereby improving patient outcomes.
Conclusion
We have implemented a phenotype-driven semiautomated workflow for WES at an academic children's hospital, which enables us to efficiently utilize WES in a frontline diagnostic setting. Aside from achieving a high diagnostic yield, we were able to reduce the turnaround time for clinical diagnosis, which impacts clinical management for a number of patients. Furthermore, the incorporation of Exomiser into the workflow has allowed us to identify a number of strong candidate variants and disease genes-some of which were supported by later publications. Combined, we established a successful WES workflow for increased diagnostic yield in the clinical setting, and strong evidence for novel variants in a research setting.
METHODS WES Workflow and Exomiser Validation
We established the workflow using 27 validation cases (Supplemental Table 2 ). These include the HapMap trio samples (NA12878, NA12891, and NA12892), 25 singleton-WES, as well as 2 trio-WES (parents and affected child) cases with known pathogenic, likely pathogenic, and VUS selected by the clinical laboratory directors. The samples were coded and the data were processed and analyzed in a blinded manner to determine the analytical and clinical accuracy, respectively.
The FreeBayes variant caller failed to call a 13-bp deletion in the 5 ′ region of RB1 exon 17 (NM_000321.2) for one case (Supplemental Table 2 , validation case 19). For the other 26 cases with 34 previously reported variants, including 27 pathogenic and likely pathogenic variants and seven VUSs, manual review of the exome data in a blinded manner achieved (26/ 26) 100% concordance rate with the prior diagnoses.
Additionally, we used Exomiser for 26 validation cases (except validation case 19) with known positive results. For pathogenic and likely pathogenic variants, Exomiser ranked 76% (22/29) variants in first place and 24% (7/29) in the second to sixth place. One likely pathogenic MLH1 variant (Validation case 16) was reported as an incidental finding and was ranked in the sixth place under the AD model because of partial phenotype overlap. For the seven VUSs, Exomiser ranked three in the first place, one in the second place, one in the seventh place, one in the 16th place and one unranked (Supplemental Table 2 ). For validation case 12, Exomiser initially ranked the known pathogenic variant in seventh place using a general HPO term "HP:0000819 Diabetes mellitus". When a more specific HPO term "HP:0004904 Maturity-onset diabetes of the young" was used, however, the ranking was elevated to first place.
Clinical WES for Patients
A total of 106 consecutive, unselected patients were referred to the Center for Personalized Medicine (CPM) for WES testing from inpatient units and outpatient clinics at the Children's Hospital Los Angeles (CHLA) (Supplemental Table 1 ). Genetic counseling and consent was required prior to WES and parents were provided with an option to receive incidental or secondary findings (Kalia et al. 2017; Green et al. 2013 ). This study was reviewed and approved by the CHLA Institutional Review Board.
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Exome Sequencing Library Preparation, Sequencing, and Bioinformatics Pipeline DNA was extracted from peripheral blood using a commercially available kit (Promega Maxwell RSC DNA Extraction Kit). The WES library was generated using the Agilent SureSelect Human All Exon V6 plus a custom mitochondrial genome capture kit, designed in collaboration with Agilent for consistent coverage across the mitochondrial genome (Falk et al. 2012 ). Paired-end 2 × 100 bp sequencing was performed using the Illumina NextSeq 500 sequencing system. The overall exome sequencing workflow is illustrated in Figure 2 , and the bioinformatics methodologies are detailed in the Supplemental Information. In brief, we used a combination of the bcbio pipeline (https://github.com/chapmanb/bcbionextgen), custom scripts and open-source bioinformatics tools to fully automate quality control (QC), sequence alignment, coverage analysis, variant calling, and initial filtering based on ExAC (Exome Aggregation Consortium, http://exac.broadinstitute.org/) allele 
Variant Calling with Edico DRAGEN Genome Pipeline
We also implemented the DRAGEN (Dynamic Read Analysis for Genomics) Genome pipeline from Edico Genome for fast FASTQ to VCF variant analysis, at roughly 4 min per exome. The DRAGEN provides hardware-accelerated analysis of next-generation sequencing (NGS) data using a field-programmable gate array (FPGA). We validated the DRAGEN Genome pipeline and achieved 99.4% and 99.9% sensitivity and specificity in overall variant calling when compared with Genome In A Bottle (GIAB; https://www.nist.gov/programs-projects/ genome-bottle) calls, and 100% concordance rate for clinically significant variants for all 37 cases with positive findings.
Standardized Clinical Phenotype Encoding With HPO For each patient, a list of phenotypic key words was generated by a clinical geneticist and a genetic counselor after review of the clinical and family history, requisition form and relevant medical notes which were then mapped to standardized HPO terms (Supplemental Tables 1,  2 ; Köhler et al. 2014 Köhler et al. , 2017 Robinson et al. 2014) and captured in CPM's PhenoTips instance (Girdea et al. 2013) . A custom HPO annotator tool was used to facilitate the conversion of free-text clinical descriptions to matching HPO terms through natural language processing and weighted mapping of the descriptions against the tiered HPO terms, synonyms, and term definitions. With a free-text input of clinical phenotype descriptions, the HPO annotator prompts a list of potentially matching HPO terms through weighted mapping of the descriptions against the tiered universe of HPO term names, synonyms, and term definitions. Likely matching HPO terms are ranked by composite scores of semantic similarity. Those deemed to most accurately reflect the patient's clinical phenotype terms were selected, commented, and captured into CPM's PhenoTips instance. For downstream analysis, we also developed a custom and web-based system that generates the primary gene list based on HPO's frequent term-to-gene associations. In addition to the genes directly generated by the input term, we found genes for all the descendent terms, which are more specific, following the HPO tree structure.
A primary gene list was generated based on HPO's term-to-gene associations (Supplemental Fig. 2 ; Girdea et al. 2013 ).
Variant Filtration, Annotation, Analysis, and Interpretation Variant filtration included three major steps. First, variants were restricted to the exonic regions and splice-site junctions (5 bp into the intron). Second, synonymous variants that were not previously reported as pathogenic in the Human Gene Mutation database (HGMD) and not predicted to alter splicing were filtered out. Last, common variants with minor allele frequency (MAF) of >1% were filtered out. MAF is estimated using combined reference data sets: Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute .org) (after March 2017) and Exome Aggregation Consortium (ExAC, http://exac .broadinstitute.org) (before March 2017). The remaining variants were annotated and analyzed using a commercial platform (Agilent Cartagenia Bench Lab NGS v5.0). For WEStrio, all de novo, homozygous, hemizygous (if male), and compound heterozygous variants were manually reviewed. For inherited heterozygous variants, only variants within the primary gene list were manually reviewed. For proband-only WES, all homozygous, hemizygous, and potentially compound heterozygous variants were manually reviewed. For heterozygous variants, only those within the primary gene list were manually reviewed. Additionally, all variants previously reported as disease-causing in the HGMD or ClinVar databases were Whole-exome sequencing of pediatric patients C O L D S P R I N G H A R B O R Molecular Case Studies reviewed. If a disease-causing variant was not identified, truncating variants in genes known to cause human diseases were reviewed. Each variant was interpreted with extensive database and literature review to consider clinical relevance, inheritance pattern, family segregation, disease mechanism, and variant level evidence (e.g., population allele frequency, evolutionary conservation, computational prediction, variant location) following ACMG standards and guidelines (Richards et al. 2015) . A variant interpretation checklist was used to ensure consistency.
Integration of Automated Exomiser Prioritization
In parallel with manual review, we incorporated an automated variant prioritization tool, Exomiser ) (version 7.2.1 and subsequently 10.1.1), into our WES diagnostic workflow. The Exomiser application ranks genes and variants by combining clinical phenotype relevance and predictions as to whether the variant is deleterious . Variant prioritization is done with two methods, PhenIX and hiPHIVE, for each of three inheritance models: AD, AR and X-linked. PhenIX is based on known gene-disease associations in humans and is therefore more suitable for clinical diagnosis; hiPHIVE uses supporting evidence from functional studies in model species and protein-to-protein associations, and therefore has the potential for novel disease gene discovery. Four filters (target, frequency, pathogenicity, and inheritance) were applied to the candidate variants. All variants that were filtered out were not ranked. The remaining candidate variants were numerically ranked from the first to the final number of variants.
Exome Board Review
Relevant candidate variants selected from both manual review and the top 20 candidate variants ranked by Exomiser were reviewed in the context of patients' clinical phenotypes at the Exome Review Board. This board includes ordering physicians, clinical geneticists, laboratory directors, bioinformaticians, and genetic counselors.
Sanger Sequencing Confirmation and Follow-Up Family Segregation Studies
Sanger sequencing was performed to confirm all the clinically relevant variants prior to final reporting and for follow-up family segregation studies.
ADDITIONAL INFORMATION Data Deposition and Access
Variants reported in this study have been detailed in the Supplemental Tables. Variants have also been deposited at NCBI ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) under accession numbers SCV0006800 92.1, SCV000692541.1-SCV000692559.1, and SCV000854 432.1-SCV000854564.1. Raw sequencing data is not available under the IRB used to perform this study.
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